Overview

Precision Biopsy, LLC was formed in partnership with Allied Minds to develop and commercialize novel technology for the accurate diagnosis of prostate cancer. The company’s diagnostic technology uses advanced spectroscopy imaging techniques in combination with tissue biopsy. This unique ability seeks to eliminate random prostate biopsies that are subject to sampling errors and can lead to inaccurate grading and staging of the disease.

The scientific founders, professors Priya Werahara and John Daily of the University of Colorado, have long studied the morphology of cancer tissue. Combining their knowledge of advanced spectroscopy techniques has resulted in the ability to image the precise location of cancer in the prostate.

www.precisionbiopsy.com

Announcements

See All
30-Mar-2016

Precision Biopsy Submits Investigational Device Exemption (IDE) Application to the FDA

Precision Biopsy Submits Investigational Device Exemption (IDE) Application to the FDA to Expand Clinical Trial of Its ClariCore™ Biopsy System in Prost..

05-Oct-2015

Allied Minds’ Subsidiary Precision Biopsy Raises $33.6 Million

Allied Minds’ Subsidiary Precision Biopsy Raises $33.6 Million to Accelerate the Commercial Expansion of its ClariCore™ Biopsy System Value of Allied..

Please visit Precision Biopsy at

Contact Precision Biopsy

  • • Required
  • Captcha Image
  • Phone Email

Privacy Policy Terms of Use